Merck opens $1B vaccine plant in North Carolina
Bio Pharma Dive
MARCH 11, 2025
Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.
Trending Articles
357 
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy
Pharmaceutical Technology
MARCH 10, 2025
AstraZeneca and Ionis are intensifying their competition with Alnylam by securing an EU approval for Wainzua.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Wholemeal or Wholegrain? An Expert Explains How to Choose Your Bread.
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 12, 2025
(Laura Leyshon/Getty Images) If you head to the shops to buy bread, you’ll face a variety of different options. But it can be hard to work out the difference between all the types on sale. For instance, you might have a vague idea that wholemeal or wholegrain bread is healthy. But what’s the difference?
March 12, 2025: In This Week’s PCT Grand Rounds, Spillover as a Potential Source of Bias in Pragmatic Trials
Rethinking Clinical Trials
MARCH 12, 2025
Sean Mann In this Friday’s PCT Grand Rounds, Sean Mann of RAND will present “Spillover Due to Constraints on Care Delivery: A Potential Source of Bias in Pragmatic Clinical Trials.” The Grand Rounds session will be held on Friday, March 14, 2025, at 1:00 pm eastern. Mann is a senior policy analyst at RAND. Join the online meeting. The post March 12, 2025: In This Week’s PCT Grand Rounds, Spillover as a Potential Source of Bias in Pragmatic Trials appeared first on Rethink
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Calcium channel inhibition promotes cardiac regeneration, offering hope for heart failure treatment
Medical Xpress
MARCH 7, 2025
Researchers report a discovery in cardiac regeneration that offers new hope for the treatment of ischemic heart failure. Published in npj Regenerative Medicine, the study reveals a novel approach to promoting cardiomyocyte proliferation. The researchers are from the Michael E. DeBakey Department of Surgery at Baylor College of Medicine, the QIMR Berghofer Medical Research Institute in Brisbane, Australia, and collaborating institutions.
Novo’s Wegovy successor disappoints in second large trial
Bio Pharma Dive
MARCH 10, 2025
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly surpass Eli Lilly’s Zepbound.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
NHS patients receive UK-donated plasma medicines for first time in 30 years
Pharma Times
MARCH 6, 2025
Octapharma supports NHS in building resilient supply chain
March 10, 2025: Developing Monitoring Plans Warrants Special Attention in Pragmatic Clinical Trials
Rethinking Clinical Trials
MARCH 10, 2025
In an article published online ahead of print , leaders from the NIH Pragmatic Trials Collaboratory share lessons learned about the importance of independent oversight by a safety office or data and safety monitoring board in pragmatic clinical trials, even for trials deemed to have minimal risk. Challenges specific to pragmatic trials include: complexity, quality, and timing of a real-world data pipeline, especially in trials with many heterogeneous sites embedding of interventions in clinical
Biogen, Apple study finds smart devices can track cognition
pharmaphorum
MARCH 7, 2025
An observational study backed by Biogen has suggested that Apple smartphones and watches may be able to spot the signs of mild cognitive impairment
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
Bio Pharma Dive
MARCH 11, 2025
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.
Artificial intelligence is making clinical supply chains more efficient and more sustainable: here’s how
Pharmaceutical Technology
MARCH 10, 2025
The potential applications of artificial intelligence (AI) in biopharmaceuticals appear wide-ranging and transformative.
New weight-loss pill shows promising results
Pharma Times
MARCH 11, 2025
Oxford Medical Products targets overweight individuals
March 6, 2025: Enrollment Begins for Several of the Newest NIH Collaboratory Trials
Rethinking Clinical Trials
MARCH 6, 2025
In recent months, 5 of the newest NIH Collaboratory Trials have begun to enroll research participants. Congratulations to the study teams from ARBOR-Telehealth, BEST-ICU, Chat 4 Heart Health, I CAN DO Surgical ACP, and the MOMs Chat & Care Study for reaching this important project milestone! ARBOR-Telehealth is evaluating the use of a telehealth physical therapy strategy for patients who present to primary care clinics with low back pain in rural communities.
No evidence for 'wind turbine syndrome' claims: Windmill noise is no more stressful than traffic sounds, study suggests
Medical Xpress
MARCH 8, 2025
A team of cognitive neuroscientists and acoustic engineers at Adam Mickiewicz University, in Poland, has found no evidence that wind turbine noise causes mental impairment. In their study, published in the journal Humanities and Social Sciences Communication, the group conducted experiments exposing human volunteers to various noises and measured a range of impacts.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Beam base editing therapy gets ‘proof of concept’ in rare lung disease
Bio Pharma Dive
MARCH 10, 2025
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell by double digits.
ElevateBio taps Amazon’s genAI tools to design CRISPR therapeutics
Pharmaceutical Technology
MARCH 11, 2025
AWSs framework will speed up the analysis of ElevateBios large protein datasets, hinting at promising drug candidates.
Dementia drug neflamapimod shows positive phase 2b trial results
Pharma Times
MARCH 11, 2025
CervoMed's therapy demonstrates significant improvement in patients
Grand Rounds February 28, 2025: Behavioral Economic and Staffing Strategies To Increase Adoption of the ABCDEF Bundle in the Intensive Care Unit (BEST-ICU): Protocol, Challenges, and Major Updates (Eduard Vasilevskis, MD, MPH; Michele C. Balas PhD, RN, CCRN-K, FCCM, FAAN)
Rethinking Clinical Trials
MARCH 6, 2025
Speakers Eduard Vasilevskis, MD, MPH Professor of Medicine Department of Medicine, Division of Hospital Medicine University of Wisconsin-Madison Michele C. Balas PhD, RN, CCRN-K, FCCM, FAAN Associate Dean of Research Dorothy Hodges Olson Distinguished Professor of Nursing University of Nebraska Medical Center College of Nursing Slides Keywords Intensive Care; ICU; Implementation; Evidence-Based Practices Key Points With recent increases in survivorship for Intensive Care U
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
GenAI and the revolution of drug development
pharmaphorum
MARCH 6, 2025
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionising life sciences and drug development.
SynWeave™: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability
Bio Pharma Dive
MARCH 10, 2025
Enhancing manufacturability is crucial for reducing the risks associated with scaling production.
Roche announces hub for cardiovascular, renal and metabolism research
Pharmaceutical Technology
MARCH 10, 2025
Roche has announced the launch of the Roche Genentech Innovation Center Boston, which will serve as the companys CVRM hub.
Ammonia buildup kills liver cells but can be prevented using existing drug
Medical Xpress
MARCH 7, 2025
High levels of ammonia kill liver cells by damaging the mitochondria that power the cells. But this can be prevented using an existing drug due to start clinical trials, finds a new study in mice led by researchers from UCL.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Leqembi enters second consultation period following NICE draft guidance update
Pharma Times
MARCH 6, 2025
NICE convenes third committee meeting for additional appraisal consideration
Roche builds in obesity with $5.3bn Zealand licensing deal
pharmaphorum
MARCH 12, 2025
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
Vertex’s new pain drug gets first coverage nod from major insurer
Bio Pharma Dive
MARCH 6, 2025
Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an interim decision while a formal review continues.
Viking strikes $150m deal to secure supply of obesity drug
Pharmaceutical Technology
MARCH 11, 2025
The multi-year manufacturing deal with CordenPharma will secure future supply of VK2735 if it goes to market.
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
Do we see the same red? New qualia structure paradigm measures shared sensory experiences
Medical Xpress
MARCH 7, 2025
A team of psychologists, bioengineers and neurologists from The University of Tokyo and Monash University in Australia has tested the possibility of using a qualia structure paradigm to understand whether sensory experiences are intersubjectively equivalent. Their paper is published in the journal iScience.
Grifols clinical trial shows positive results for post-polio patients
Pharma Times
MARCH 13, 2025
Immunoglobulin therapy improves mobility in phase 2/3 study
Gates-backed game aims to raise HPV awareness in Africa
pharmaphorum
MARCH 12, 2025
Psyon is running a pilot study of a game that aims to raise awareness of HPV infection and vaccination in sub-Saharan Africa.
Roche launches new Boston center; NIH centralizes peer review
Bio Pharma Dive
MARCH 7, 2025
The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio advanced a gene therapy and Pfizer hired a scientist well versed in GLP-1 science.
Let's personalize your content